Chengfei Liu, MD, PhD
University of California, Davis
H-index: 27
North America-United States
Top articles of Chengfei Liu, MD, PhD
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
MP60-17 THERAPEUTIC RESISTANCE MODELS AND TREATMENT SEQUENCING IN ADVANCED PROSTATE CANCER | The Journal of Urology | Zachary Schaaf Shu Ning Alan Lombard Chengfei Liu Wei Lou | 2024/5 |
Dual targeting of HSP70 and AURKA improves treatment in neuroendocrine prostate cancer | Cancer Research | Pengfei Xu Joy C Yang Bo Chen Shu Ning Leyi Wang | 2024/3/22 |
IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer | Iscience | Amy R Leslie Shu Ning Cameron M Armstrong Leandro S D’Abronzo Masuda Sharifi | 2024/2/16 |
Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer | Cancers | Zachary A Schaaf Shu Ning Amy R Leslie Masuda Sharifi Xianrui Han | 2023/11/3 |
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer | Oncogene | Joy C Yang Pengfei Xu Shu Ning Logan J Wasielewski Hans Adomat | 2023/2/24 |
Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment | Journal for immunotherapy of cancer | Pengfei Xu Joy C Yang Bo Chen Christopher Nip Jonathan E Van Dyke | 2023 |
Abstract B023: Targeting noncanonical Wnt5a signaling suppresses the neural lineage network and overcomes enzalutamide resistance in advanced prostate cancer | Cancer Research | Shu Ning Wei Lou Chengfei Liu Alan Paul Lombard Leandro S D' Abronzo | 2023/6/2 |
Targeting noncanonical Wnt5a signaling suppresses the neural lineage network and overcomes enzalutamide resistance in advanced prostate cancer | Cancer Research | Shu Ning Wei Lou Chengfei Liu Joy C Yang Alan P Lombard | 2023/4/4 |
MP20-16 NOVEL FUNCTION OF PTUPB IN AKR1C3/AR/AR-V7 AXIS INHIBITION AND ENZALUTAMIDE SENSITIZATION IN ADVANCED PROSTATE CANCER | The Journal of Urology | Joy Yang Pengfei Xu Bo Chen Shu Ning Hans Adomat | 2023/4 |
Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models | Pharmacological research | Pengfei Xu Joy C Yang Shu Ning Bo Chen Christopher Nip | 2023/3/1 |
Biological evaluation of a novel AKR1C3 inhibitor in patient-derived prostate cancer cell line and xenograft models | Cancer Research | Joy C Yang Shu Ning Hans Adomat Martin Gleave Allen Gao | 2022/6/15 |
PD07-02 Targeting Wnt5a/Fzd2 signaling overcomes resistance to enzalutamide in advanced prostate cancer | The Journal of Urology | Shu Ning Chengfei Liu Wei Lou Alan Lombard Leandro D'Abronzo | 2022/5 |
Evaluating the efficacy of a novel AKR1C3 inhibitor in patient-derived prostate cancer cell line and xenograft models | Joy C Yang Shu Ning Hans Adomat Martin Gleave Allen C Gao | 2022/5/1 | |
Bioengineered BERA-Wnt5a siRNA targeting Wnt5a/FZD2 signaling suppresses advanced prostate cancer tumor growth and enhances enzalutamide treatment | Molecular cancer therapeutics | Shu Ning Chengfei Liu Wei Lou Joy C Yang Alan P Lombard | 2022/10/7 |
Treatment of metastatic prostate cancer | 2022/1/4 | ||
Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes | Communications Medicine | Shu Ning Jinge Zhao Alan P Lombard Leandro S D’Abronzo Amy R Leslie | 2022/9/21 |
The immunotherapy and immunosuppressive signaling in therapy-resistant prostate cancer | Pengfei Xu Logan J Wasielewski Joy C Yang Demin Cai Christopher P Evans | 2022/7/22 | |
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer | Scientific reports | Mamta Parikh Chengfei Liu Chun-Yi Wu Christopher P Evans Marc Dall’Era | 2021/3/18 |
ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling | Oncogene | Chengfei Liu Cameron M Armstrong Shu Ning Joy C Yang Wei Lou | 2021/9/2 |
Therapeutic targeting of MDR1 expression by RORγ antagonists resensitizes cross-resistant CRPC to taxane via coordinated induction of cell death programs | Molecular cancer therapeutics | Yongqiang Wang Zenghong Huang Christopher Z Chen Chengfei Liu Christopher P Evans | 2020/2/1 |
Co-Authors
